Licensing · Global (LMICs) · Announced 16 Nov 2026

Gilead Sciences → Ferozsons Laboratories

Gilead signed a royalty-free voluntary licence with Pakistan's Ferozsons Laboratories to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis across 127 mainly low- and lower-middle-income countries.

Parties: Gilead Sciences (United States) → Ferozsons Laboratories (Pakistan)

Deal type
Licensing
Value
Royalty-free
Territory
127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
Therapeutic area
Infectious Disease
Asset
obeldesivir
Announced
16 Nov 2026

Our analysis

Why this matters

On 16 November 2026 Gilead Sciences announced royalty-free voluntary licences with Ferozsons Laboratories, Dr. Reddy's Laboratories and Eva Pharma for obeldesivir, an investigational oral antiviral being studied for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licences cover 127 countries, primarily low- and lower-middle-income, including all African countries with reported cases in the current outbreak.

The agreements precede results from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved for any indication; supply under the licences requires supportive clinical data and regulatory authorisations.

The full analysis is free to read with a work email on this page.

Source: Gilead Sciences press release

More deals involving Gilead Sciences or Ferozsons Laboratories

Latest deals

All Global (LMICs) deals → · All licensing deals → · Browse all emerging-market pharma deals →